TCBP TC BioPharm Ltd: Long-Term Debt to Capital Coefficient

Symbol and logo of brand TC BioPharm Ltd (TCBP)

TC Biopharm is developing a unique environment for combating tumors using specific T-cells and closed medical protocols. This daily price chart reflects the asset's dynamics, where the indicator stands at 0.63. TC Biopharm is targeting the massive leukemia therapy segment by expanding the number of trials. Management is focused on creating advanced treatments for infections and cancer, leveraging its own scientific research.

TCBP - TC BioPharm (Holdings) Plc Long-Term Debt to Equity over the range 04/28/2023 - 03/29/2025

Comprehensive metric breakdowns and analytics for TC Biopharm (TCBP)

- price and consensus price forecast:
Quote Chart TC BioPharm (Holdings) Plc|TCBP - Analyst Consensus Forecast
- market capitalization data:
Market Value TC BioPharm (Holdings) Plc|TCBP - Enterprise Value
- book capitalization data:
Book Value per Share TC BioPharm|TCBP - Company Book Value|Market Value to Book Value tcbiopharm.com|TCBP - Aggregate Company Assets
- debt and liquidity data:
Total Debt to Equity Ratio TC Biopharm|TCBP - Long-Term Debt to Capital|Short-Term Debt to Capital tcbiopharm.com|TCBP - Company Total Debt|Debt to Net Assets Ratio TC BioPharm (Holdings) Plc|TCBP - Company Long-Term Debts|Short-Term Debt Volume TC BioPharm
Initial company analysis:TCBP, TC BioPharm (Holdings) Plc
Core merchandise of TC Biopharm

For TC Biopharm, analyzing the debt load is critical when assessing the resilience of this defensive asset. This long-term debt-to-equity ratio compares the volume of loans with maturities exceeding one year against the total equity. The metric reveals hidden liquidity deficits, preventing investments in "value traps." Stable demand for unique medical developments minimizes debt service risks. A low indicator level confirms the company's financial autonomy within the sovereign cycle.

Direct competitors

Long-Term Liabilities to Equity argenx N.V.|BioNTech Group (BNTX) - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient Abivax S.A. (ABVX)|Long-Term Debt to Capital ADMA (ADMA Biologics)|protagonist-inc.com - Long-Term Debt to Capital|Long-Term Debt to Equity Immunovant (IMVT)|KNSA: Long-Term Debt to Capital Coefficient|GRFS (Grifols Group) - Long-Term Debt to Equity|Adaptive Biotechnologies Inc. (ADPT) - Long-Term Debt to Equity Ratio|CLDX (Celldex Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital auriniapharma.com (AUPH)|BioCryst Pharmaceuticals (BCRX) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient Vera Therapeutics Inc (VERA)|Long-Term Debt to Capital DNTH|Pharvaris Pharma - Ratio of Long-Term Indebtedness to Capital|ABCL: Long-Term Debt to Equity|TRML: Long-Term Debt to Equity Ratio|PGEN (Precigen) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Pharming Group NV|NKTR (Nektar) - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital UPB|Long-Term Debt to Equity Zenas Biopharma Inc ZBIO|Long-Term Debt to Capital Ratio immunome.com (IMNM)|GOSS: Long-Term Debt to Capital|KALV - Long-Term Liabilities to Capital|Long-Term Debt to Equity Ratio Septerna Corp SEPN|PVLA - Long-Term Loans to Capital Ratio|SVRA (Savara Inc.) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio rigel.com|ANAB - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient Astria Therapeutics Inc|Long-Term Debt to Capital enGene Bio (ENGN)|Long-Term Debt to Equity rapt.com (RAPT)|Long-Term Debt to Capital JBIO|aclaristx.com - Ratio of Long-Term Indebtedness to Capital|KYTX (Kyverna Therapeutics, Inc.) - Long-Term Debt to Equity|TLSA: Long-Term Liabilities to Capital|Long-Term Debt to Equity Cabaletta Bio, Inc (CABA)|Ventyx Biosciences, Inc (VTYX) - Long-Term Liabilities to Equity|THTX - Long-Term Debt to Capital|Long-Term Debt to Capital Coefficient avalotx.com|Long-Term Debt to Capital ELDN|Long-Term Debt to Capital AGEN (Agenus, Inc.)|Long-Term Debt to Equity Climb Bio, Inc.|zurabio.com - Long-Term Debt to Capital Coefficient|ATYR: Long-Term Debt to Equity|Adagene (ADAG) - Long-Term Debt to Equity Ratio|IMA - Long-Term Debt to Equity Ratio|Shattuck Labs (STTK) - Long-Term Loans to Capital Ratio|Long-Term Debt to Capital EQ|Long-Term Debt to Equity Ratio Connect Pharma|Long-Term Debt to Capital Immunic, Inc. (IMUX)|Long-Term Debt to Equity ATRA (atarabio.com)|InflaRx (IFRX) - Long-Term Debt to Equity|X4 Pharmaceuticals Inc. - Long-Term Liabilities to Equity|Long-Term Debt to Equity Adicet|CELU - Long-Term Liabilities to Equity|Long-Term Debt to Capital INmune Bio, Inc. INMB|barinthusbio.com (BRNS) - Long-Term Debt to Capital Coefficient|KZR (Kezar Life Sciences, Inc.) - Long-Term Debt to Capital|Long-Term Debt to Capital SABS|Akari Therapeutics plc (AKTX) - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient ENLV (enlivex.com)|Q32 Bio - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio geovax.com GOVX|Edesa Biotech - Long-Term Debt to Capital|iBio Inc (IBIO) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio carismatx.com CARM|XTL Bio (XTLB) - Long-Term Debt to Capital Coefficient|BOLT: Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital HCWB|Long-Term Debt to Equity APVO (Aptevo Therapeutics)|Long-Term Debt to Equity Ratio AIM (aimimmuno.com)|Aditxt, Inc. - Long-Term Debt to Equity|GRI - Long-Term Debt to Equity Ratio|XORTX Therapeutics Inc. - Long-Term Debt to Equity Ratio|HIND: Long-Term Debt to Capital|Long-Term Debt to Equity Revelation Biosciences, Inc.|Indaptus Therapeutics Inc (INDP) - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital SCNI (Scinai)|Long-Term Liabilities to Capital CalciMedica Corp (CALI)|Long-Term Debt to Equity Ratio Affimed|Long-Term Loans to Capital Ratio allakos.com (ALLK)|HOOKIPA Pharma - Long-Term Debt to Capital|IGMS - Long-Term Debt to Equity Ratio|Long-Term Debt to Equity Ratio iTeos (ITOS)|OCEA - Long-Term Debt to Capital Coefficient|Third Harmonic Bio (THRD) - Long-Term Debt to Capital